Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Patent metadata

Field	Value
Publication number	US-11305015-B2
Application number	US-201916696403-A
Country	US
Kind code	B2
Filing date	Nov 26, 2019
Priority date	Oct 18, 2016
Publication date	Apr 19, 2022
Grant date	Apr 19, 2022

Abstract

CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.

First claim

The invention claimed is:

1. A cytomegalovirus (CMV) vector comprising:
(a) a first nucleic acid sequence that encodes at least one heterologous antigen; and
(b) a second nucleic acid sequence comprising a first heterologous microRNA recognition element (MRE) operably linked to a UL122 (IE2) or UL79 CMV gene, wherein the MRE is complementary to a microRNA that is expressed by a cell of endothelial lineage, wherein the microRNA is miR-126-3p, miR-130a, miR-210, miR-221/222, miR-378, miR-296, or miR-328.

2. The CMV vector of claim 1 , wherein the microRNA is miR-126-3p.

3. The CMV vector of claim 1 , wherein the at least one heterologous antigen comprises a pathogen-specific antigen, a tumor antigen, a tissue-specific antigen, or a host self-antigen.

4. The CMV vector of claim 3 , wherein the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.

5. The CMV vector of claim 3 , wherein the pathogen specific antigen is derived from a pathogen selected from the group consisting of: human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.

6. The CMV vector of claim 3 , wherein the tumor antigen is related to a cancer selected from the group consisting of: acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.

7. The CMV vector of claim 1 , wherein the CMV vector does not express an active UL82 (pp71) protein, or an ortholog thereof.

8. The CMV vector of claim 1 , wherein the CMV vector does not express an active US11 protein, or an ortholog thereof.

9. The CMV vector of claim 1 , wherein the CMV vector does not express an active UL82 (pp71) protein or an active US11 protein, or orthologs thereof.

10. The CMV vector of claim 1 , wherein the CMV vector is a human CMV vector (HCMV), a cynomolgus CMV (CyCMV) vector, or a rhesus CMV (RhCMV) vector.

11. A method of generating an immune response in a subject to at least one heterologous antigen, the method comprising:
administering to the subject the CMV vector of claim 1 in an amount effective to elicit a CD8+ T cell response to the at least one heterologous antigen.

12. The method of claim 11 , further comprising administering to the subject a second CMV vector comprising a nucleic acid sequence that encodes at least one heterologous antigen.

13. The method of claim 12 , wherein the at least one heterologous antigen of the first CMV vector and the second CMV vector are the same antigen.

14. The method of claim 12 , wherein the second CMV vector is administered before, concurrently with, or after the first CMV vector.

15. The method of claim 11 , wherein the subject has been previously exposed to CMV.

16. The method of claim 11 , wherein the subject is a human or nonhuman primate.

17. The method of claim 11 , wherein administering the CMV vector comprises subcutaneous, intravenous, intramuscular, intraperitoneal, or oral administration of the CMV vector.

18. A cytomegalovirus (CMV) vector comprising:
(a) a first nucleic acid sequence that encodes at least one heterologous antigen;
(b) a second nucleic acid sequence comprising a first heterologous microRNA recognition element (MRE) operably linked to a UL122 (IE2) or UL79 CMV gene, wherein the MRE is complementary to a microRNA that is expressed by a cell of endothelial lineage; and
(c) a third nucleic acid sequence comprising a second heterologous MRE operably linked to a UL122 (IE2) or UL29-UL79 CMV gene, wherein the MRE is complementary to a microRNA that is expressed by a cell of myeloid lineage, wherein the first microRNA is miR-126-3p, miR-130a, miR-210, miR-221/222, miR-378, miR-296, or miR-328 and the second microRNA is miR-142-3p, miR-223, miR-27a, miR-652, miR-155, miR-146a, miR-132, miR-21, or miR-125.

19. The CMV vector of claim 18 , wherein the first microRNA is miR-126-3p.

Assignees

• Univ Oregon Health & Science

Inventors

• Picker Louis
• Hansen Scott
• Frueh Klaus
• Malouli Daniel
• Nelson Jay
• Sacha Jonah
• Hancock Meaghan

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K40/46

  Viral antigens · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title